market size8 Nov 2017 15:30
From the AGM Trading update September 2017:
http://www.reneuron.com/investors/presentations/
Indication
Assumptions to 2026
Peak Sales ($bn)
CTX for stroke
1.76 million strokes/year (total US/EU/Japan) 85% survival, 85 % ischaemic
Peak penetration 5% US/EU/Japan
Treatment cost $40,000 EU to $60,000 US/Japan
1.1 - 3.9
hRPC for RP
Prevalence 1:4000, ~244,000 cases (total US/EU/Japan) Peak penetration 7.5% US/ EU
Per-eye treatment cost $50,000 EU to $75,000 US/Japan
0.5 - 1.8